Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.

NCT Number	NCT05068232
Lead Sponsor	University of Chicago
Conditions	Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Enrollment	49 participants
Start Date	2022-08-19
Primary Completion	2027-10-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-04